Boston Scientific Corp. (BSX) Tops Q4 EPS by 5c, Offers Q1 Sales Guidance
Tweet
Share
E-mailGet Alerts BSX Hot Sheet
Price: $72.91 --0%
Revenue Growth %: +13.7%
Financial Fact:
Cost of products sold: 594M
Today's EPS Names:
UXIN, TOWN, NRIM, More
Revenue Growth %: +13.7%
Financial Fact:
Cost of products sold: 594M
Today's EPS Names:
UXIN, TOWN, NRIM, More
Join SI Premium – FREE
Boston Scientific Corp. (NYSE: BSX) reported Q4 EPS of $0.13, $0.05 better than the analyst estimate of $0.08. Revenue for the quarter came in at $1.85 billion versus the consensus estimate of $1.91 billion.
Boston Scientific Corp. sees Q1 2012 revenue of $1.83-$1.9 million, versus the consensus of $1.9 million.
For earnings history and earnings-related data on Boston Scientific Corp. (BSX) click here.
Boston Scientific Corp. sees Q1 2012 revenue of $1.83-$1.9 million, versus the consensus of $1.9 million.
For earnings history and earnings-related data on Boston Scientific Corp. (BSX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Scientific (BSX) PT Lowered to $85 at Mizuho
- Caterpillar (CAT) tops earnings expectations but sales volume declines
- Merck (MRK) hikes outlook for 2024 as Q1 print beats analyst estimates
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
